Insider Selling: Boston Scientific Co. (NYSE:BSX) EVP Sells 1,201 Shares of Stock

Boston Scientific Co. (NYSE:BSX) EVP John Bradley Sorenson sold 1,201 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the sale, the executive vice president now owns 25,443 shares of the company’s stock, valued at $2,704,845.33. The trade was a 4.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

John Bradley Sorenson also recently made the following trade(s):

• On Wednesday, February 12th, John Bradley Sorenson sold 6,389 shares of Boston Scientific stock. The shares were sold at an average price of $105.06, for a total value of $671,228.34.
• On Friday, February 7th, John Bradley Sorenson sold 6,528 shares of Boston Scientific stock. The shares were sold at an average price of $104.97, for a total value of $685,244.16.
• On Thursday, January 2nd, John Bradley Sorenson sold 4,119 shares of Boston Scientific stock. The shares were sold at an average price of $90.02, for a total value of $370,792.38.

Boston Scientific Stock Down 0.7 %

BSX stock traded down $0.79 during trading on Tuesday, hitting $105.32. 6,505,334 shares of the company’s stock traded hands, compared to its average volume of 6,108,297. The firm has a market capitalization of $155.22 billion, a P/E ratio of 84.26, a PEG ratio of 2.79 and a beta of 0.80. The business has a fifty day simple moving average of $96.79 and a two-hundred day simple moving average of $88.61. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 1 year low of $65.33 and a 1 year high of $107.17.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. Sell-side analysts anticipate that Boston Scientific Co. will post 2.83 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on BSX shares. StockNews.com upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday, January 29th. UBS Group increased their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a report on Friday, February 7th. Citigroup increased their price target on shares of Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Piper Sandler increased their price target on shares of Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a report on Monday, February 3rd. Finally, Mizuho increased their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Thursday, October 24th. One investment analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $107.39.

Institutional Investors Weigh In On Boston Scientific

Institutional investors and hedge funds have recently made changes to their positions in the stock. Investment Management Corp VA ADV acquired a new stake in shares of Boston Scientific during the fourth quarter worth $25,000. Colonial Trust Co SC lifted its stake in shares of Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 260 shares during the period. TFC Financial Management Inc. lifted its stake in shares of Boston Scientific by 308.8% during the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 210 shares during the period. Global Wealth Strategies & Associates lifted its stake in shares of Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 250 shares during the period. Finally, West Oak Capital LLC acquired a new stake in shares of Boston Scientific during the fourth quarter worth $29,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.